Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 379,500 shares, an increase of 600.2% from the March 31st total of 54,200 shares. Based on an average trading volume of 1,170,000 shares, […]
25.04.2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, .
Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) major shareholder Gilead Sciences, Inc. acquired 485,250 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was purchased at an average price of $0.76 per share, for a total transaction of $368,790.00. Following the completion of the acquisition, the insider now owns […]
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer in the.